Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study

Advances in Therapy

Volumn 26, Issue 2, 2009, Pages 185-193

  Simpson, Kit N ^a   Rajagopalan, Rukmini ^b   Dietz, Birgitta ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b ABBOTT LABORATORIES   (United States)

^c ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Boosted atazanavir; Budget impact model; CASTLE study; Cost effectiveness analysis; Lopinavir ritonavir

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATAZANAVIR PLUS RITONAVIR; CHOLESTEROL; LOPINAVIR PLUS RITONAVIR;

ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; POPULATION DISTRIBUTION; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SMOKING;

ANTI-HIV AGENTS; BUDGETS; CD4 LYMPHOCYTE COUNT; CORONARY DISEASE; COST SAVINGS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COSTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MODELS, ECONOMETRIC; OLIGOPEPTIDES; PYRIDINES; PYRIMIDINONES; QUALITY-ADJUSTED LIFE YEARS; RITONAVIR; SMOKING; UNITED STATES;

EID: 73449118935     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0141-8     Document Type: Article

References (14)

1. R.Y. Chen N.A. Accortt A.O. Westfall 2006 Distribution of health care expenditures for HIV-infected patients Clin Infect Dis 42 1003 1010 16511767 10.1086/500453 1:CAS:528:DC%2BD28XhtV2hsb7E
2. K.N. Simpson M. Luo E.C.G. Chumney M.S. King S. Brun 2007 Cost-effectiveness of lopinavir/ritonavir compared to atazanavir in antiretroviral-naïve patients: modeling the combined effects of HIV and heart disease Clin Drug Invest 27 67 74 10.2165/00044011-200727010-00006 1:CAS:528:DC%2BD2sXislShtrc%3D
3. R.B. D'Agostino M.W. Russell D.M. Huse 2000 Primary and subsequent coronary risk appraisal: new results from the Framingham study Am Heart J 139 273 281
4. Friis-Moller N, Reiss P, El-Sadr W, et al. Exposure to PIs and NNRTI and risk of myocardial infarction: results of the D:A:D study. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5-8, 2006; Denver, Colorado. Session 35. Oral abstract 144.
5. J.M. Molina J. Andrade-Villanueva J. Echevarria 2008 Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study Lancet 372 646 655 18722869 10.1016/S0140-6736(08)61081-8 1:CAS:528: DC%2BD1cXhtVagu7jM
6. A.C. Ghani F. de Wolf N.M. Ferguson 2001 Surrogate markers for disease progression in treated HIV infection J Acquir Immune Defic Syndr 28 226 231 11694828 1:CAS:528:DC%2BD38XhtlWisrY%3D
7. A.C. Ghani W.E. Henley C.A. Donnelly S. Mayer R.M. Andersen 2001 Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases AIDS 15 1133 1142 11416715 10.1097/00002030-200106150- 00008 1:CAS:528:DC%2BD3MXltFeit74%3D (Pubitemid 32549864)
8. A. Mocroft L. Ruiz P. Reiss 2003 Virological rebound after suppression on highly active antiretroviral therapy AIDS 17 1741 1751 12891060 10.1097/00002030-200308150-00003 (Pubitemid 37000092)
9. D. Castiel C. Herve M. Gaillard 1992 Cost-utility analysis of early thrombolytic therapy Pharmacoeconomics 1 438 442 10147023 10.2165/00019053- 199201060-00004 1:STN:280:ByuK3cfit1Y%3D
10. Fleming T, ed. Red Book 2007: Pharmacy's Fundamental Reference. Montvale NJ: Thompson Healthcare; 2007.
11. K.N. Simpson M.P. Luo E.G. Chumney E. Sun S. Brun T. Ashraf 2004 Cost effectiveness of using lopinavir/ritonavir vs. nelfinavir as the first highly active antiretroviral regimen for HIV infection HIV Clin Trials 5 294 304 15562370 10.1310/WT81-MEM4-5C4L-CHPK (Pubitemid 39545402)
12. K.N. Simpson G. Roberts C.B. Hicks 2008 Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States HIV Clin Trials 9 224 236 10.1310/hct0904-225
13. P. Dolan 1998 Modeling valuations for EuroQoL health states Med Care 35 1095 1108 10.1097/00005650-199711000-00002
14. J.M. Mrus M.S. Yi K.A. Freedberg 2003 Utilities derived from visual analog scale scores in patients with HIV/AIDS Med Decis Making 23 414 421 14570299 10.1177/0272989X03256884 (Pubitemid 37169365)